Imjudo Injection, Solution
Product Images NDC 0310-4535

5 FDA label images from Astrazeneca Pharmaceuticals Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imjudo (NDC 0310-4535). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Fig 1)

Figure 1 (Fig 1)
A Kaplan-Meier survival curve chart comparing the probability of overall survival over time from randomization in months for two groups labeled STRIDE and S. The chart includes solid and dashed lines representing survival probabilities and indicates censored data points along the curves.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A Kaplan-Meier survival curve graph depicting the probability of overall survival (OS) over time in months from randomization. Two treatment groups are compared: IMJUDO plus durvalumab with platinum-based chemotherapy, and platinum-based chemotherapy alone. The y-axis represents probability of OS, and the x-axis shows time in months up to 48 months.*
FDA Label Image

Figure_2_data (Figure 2 Data)

Figure_2_data (Figure 2 Data)
A data table presenting the number of patients at risk over time in months (0 to 45) for two treatment groups: IMJUDO (tremelimumab) combined with durvalumab plus platinum-based chemotherapy, and platinum-based chemotherapy alone. Patient counts decrease over the time points for both groups, starting near 338 and 337 respectively at month 0 and reaching 0 by month 45.*
FDA Label Image

300_mg (300mg Treme)

300_mg (300mg Treme)
Label for IMJUDO (tremelimumab-actl) Injection, a human prescription drug for intravenous infusion after dilution. The label indicates a strength of 300 mg/15 mL (20 mg/mL) in a single-dose vial. It includes instructions for pharmacists to dispense the Medication Guide to patients. The label also features the AstraZeneca logo and NDC 0310-4535-30.*
FDA Label Image

25_mg (25mg Treme)

25_mg (25mg Treme)
Label for IMJUDO (tremelimumab-actl) Injection, 25 mg/1.25 mL (20 mg/mL) single-dose vial, for intravenous infusion after dilution. The label includes directions for pharmacists to dispense the accompanying medication guide. It is manufactured by AstraZeneca Pharmaceuticals LP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.